{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:52:04Z","timestamp":1791211924206,"version":"4.1.0"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008476","name":"University of California, Irvine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL147562"],"award-info":[{"award-number":["HL147562"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U18 EB029354"],"award-info":[{"award-number":["U18 EB029354"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.trsl.2021.03.007","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T20:49:08Z","timestamp":1615322948000},"page":"141-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Pain in sickle cell disease: current and potential translational therapies"],"prefix":"10.1016","volume":"234","author":[{"given":"Varun","family":"Sagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpna","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2021.03.007_bib0001","unstructured":"Centers for Disease Control and Prevention. CDC Wonder. Accessed December 24, 2020. https:\/\/wonder.cdc.gov\/."},{"key":"10.1016\/j.trsl.2021.03.007_bib0002","unstructured":"Can an inflammatory index predict sickle cell pain? Accessed December 25, 2020. https:\/\/heal.nih.gov\/news\/stories\/biosensing-blood-test"},{"key":"10.1016\/j.trsl.2021.03.007_bib0003","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","article-title":"Sickle cell pain: a critical reappraisal","volume":"120","author":"Ballas","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0004","doi-asserted-by":"crossref","first-page":"e79923","DOI":"10.1371\/journal.pone.0079923","article-title":"Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study","volume":"8","author":"Darbari","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.03.007_bib0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0006","unstructured":"National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: Expert Panel, 2014. Accessed December 24, 2020."},{"key":"10.1016\/j.trsl.2021.03.007_bib0007","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2017-05-782003","article-title":"Targeting novel mechanisms of pain in sickle cell disease","volume":"130","author":"Tran","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/540154","article-title":"Morphine for the treatment of pain in sickle cell disease","volume":"2015","author":"Gupta","year":"2015","journal-title":"Sci World J"},{"key":"10.1016\/j.trsl.2021.03.007_bib0009","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/bja\/aet221","article-title":"Morphine stimulates platelet-derived growth factor receptor-\u03b2 signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo","volume":"111","author":"Weber","year":"2013","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.trsl.2021.03.007_bib0010","first-page":"109","article-title":"Morphine promotes renal pathology in sickle mice","volume":"5","author":"Weber","year":"2012","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.trsl.2021.03.007_bib0011","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ncpneph1008","article-title":"Sickle cell disease and the kidney","volume":"5","author":"Scheinman","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0013","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1172\/JCI64578","article-title":"Extracellular hemin crisis triggers acute chest syndrome in sickle mice","volume":"123","author":"Ghosh","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.03.007_bib0014","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0015","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/bloodadvances.2018026898","article-title":"Morphine promotes neovascularizing retinopathy in sickle transgeneic mice","volume":"3","author":"Gupta","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.trsl.2021.03.007_bib0016","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/156720206778018767","article-title":"Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells","volume":"3","author":"Chen","year":"2006","journal-title":"Curr Neurovasc Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0017","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ajh.21213","article-title":"Pilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisis","volume":"83","author":"Koch","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0018","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/bloodadvances.2018024299","article-title":"Effect of chronic opioid therapy on pain and survival in a humanized mouse model of sickle cell disease","volume":"3","author":"Tran","year":"2019","journal-title":"Blood Adv"},{"issue":"1 Suppl 1","key":"10.1016\/j.trsl.2021.03.007_bib0019","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.amepre.2016.02.012","article-title":"Chronic opioid therapy and central sensitization in sickle cell disease","volume":"51","author":"Carroll","year":"2016","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0020","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.trsl.2021.03.007_bib0021","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1001\/jama.2009.1811","article-title":"Treatment of sickle cell pain: fostering trust and justice","volume":"302","author":"Zempsky","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.03.007_bib0022","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0885-3924(97)00019-5","article-title":"Sickle cell-related pain: perceptions of medical practitioners","volume":"14","author":"Shapiro","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.trsl.2021.03.007_bib0023","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/082585970502100403","article-title":"Physicians\u2019 attitude and practices in sickle cell disease pain management","volume":"21","author":"Labb\u00e9","year":"2005","journal-title":"J Palliat Care"},{"key":"10.1016\/j.trsl.2021.03.007_bib0024","doi-asserted-by":"crossref","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention's 2016 opioid guideline","volume":"169","author":"Bohnert","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain \u2014 United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.trsl.2021.03.007_bib0026","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMp1904190","article-title":"No shortcuts to safer opioid prescribing","volume":"380","author":"Dowell","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0027","unstructured":"CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for Chronic Pain. Accessed December 25, 2020. https:\/\/www.cdc.gov\/media\/releases\/2019\/s0424-advises-misapplication-guideline-prescribing-opioids.html"},{"key":"10.1016\/j.trsl.2021.03.007_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4410","article-title":"Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study","volume":"2","author":"Sinha","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.trsl.2021.03.007_bib0029","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1553-2712.2007.tb01801.x","article-title":"Emergency department management of acute pain episodes in sickle cell disease","volume":"14","author":"Tanabe","year":"2007","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0030","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/pm\/pnw074","article-title":"The opioid drug epidemic and sickle cell disease: guilt by association","volume":"17","author":"Ruta","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0031","doi-asserted-by":"crossref","first-page":"E345","DOI":"10.1002\/ajh.25233","article-title":"Opioid utilization patterns in United States individuals with sickle cell disease","volume":"93","author":"Ballas","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0032","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6604057","article-title":"COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia","volume":"97","author":"Farooqui","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2021.03.007_bib0033","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1463-1318.2006.00998.x","article-title":"Prospective randomized, double-blind, placebo-controlled study of pre- and postoperative administration of a COX-2-specific inhibitor as opioid-sparing analgesia in major colorectal surgery","volume":"9","author":"Sim","year":"2007","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.trsl.2021.03.007_bib0034","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4065\/83.10.1116","article-title":"Development of peripheral opioid antagonists\u2019 new insights into opioid effects","volume":"83","author":"Moss","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.trsl.2021.03.007_bib0035","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2147\/DDDT.S221278","article-title":"The Use of Peripheral \u03bc-Opioid Receptor Antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety","volume":"14","author":"Pergolizzi","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.trsl.2021.03.007_bib0036","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/jgh.14586","article-title":"Peripherally acting \u03bc-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis","volume":"34","author":"Nishie","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0037","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/j.pain.0000000000001736","article-title":"Pain, opioid therapy, and survival: a needed discussion","volume":"161","author":"Novy","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0038","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1523\/JNEUROSCI.2950-18.2019","article-title":"Growth factor signaling regulates mechanical nociception in flies and vertebrates","volume":"39","author":"Lopez-Bellido","year":"2019","journal-title":"J Neurosci"},{"key":"10.1016\/j.trsl.2021.03.007_bib0039","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nm.2633","article-title":"Blockade of PDGFR-\u03b2 activation eliminates morphine analgesic tolerance","volume":"18","author":"Wang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MAJ.0000000000000228","article-title":"Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia","volume":"347","author":"Murphy","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.trsl.2021.03.007_bib0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.2011.08670.x","article-title":"Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?","volume":"155","author":"Stankovic Stojanovic","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0042","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood-2013-04-498105","article-title":"Mast cell activation contributes to sickle cell pathobiology and pain in mice","volume":"122","author":"Vincent","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0043","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.16671","article-title":"Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease","volume":"190","author":"Noomuna","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0044","first-page":"109","article-title":"Morphine promotes renal pathology in sickle mice","volume":"5","author":"Weber","year":"2012","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.trsl.2021.03.007_bib0045","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2021.03.007_bib0046","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/asheducation-2013.1.362","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"2013","author":"Manwani","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.trsl.2021.03.007_bib0047","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0022-2143(97)90005-6","article-title":"Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia","volume":"129","author":"Wun","year":"1997","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0048","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/ATVBAHA.110.211615","article-title":"P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease","volume":"30","author":"Polanowska-Grabowska","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0049","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.blre.2006.06.001","article-title":"Platelet-neutrophil-interactions: linking hemostasis and inflammation","volume":"21","author":"Zarbock","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.trsl.2021.03.007_bib0050","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0051","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3324\/haematol.2018.211391","article-title":"Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controls","volume":"105","author":"Shah","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2021.03.007_bib0052","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ajh.24858","article-title":"Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain","volume":"92","author":"Khaleel","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0053","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200065","article-title":"Nociceptors protect sickle cell disease mice from vaso-occlusive episodes and chronic organ damage","volume":"218","author":"Xu","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0054","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0056","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(97)90062-7","article-title":"Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells","volume":"130","author":"Niihara","year":"1997","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0057","first-page":"4","article-title":"L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells","volume":"5","author":"Niihara","year":"2005","journal-title":"BMC Blood Disord"},{"key":"10.1016\/j.trsl.2021.03.007_bib0058","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0059","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25139","article-title":"Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access","author":"Blyden","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0060","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0061","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0062","article-title":"Efficacy and safety of rivipansel (GMI-1070) in the treatment of vaso-occlusive crisis in hospitalized patients with sickle cell disease: results from the RESET Phase 3 Study","volume":"7","author":"Dampier","year":"2020","journal-title":"J Sickle Cell Di Hemoglobin"},{"key":"10.1016\/j.trsl.2021.03.007_bib0063","unstructured":"Figueiredo M. Rivipansel for SCD Granted FDA's rare pediatric disease designation. Accessed December 24, 2020. https:\/\/sicklecellanemianews.com\/2020\/10\/08\/rivipansel-for-sickle-cell-disease-granted-fda-rare-pediatric-disease-designation\/"},{"key":"10.1016\/j.trsl.2021.03.007_bib0064","doi-asserted-by":"crossref","first-page":"H39","DOI":"10.1152\/ajpheart.00162.2008","article-title":"Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress","volume":"295","author":"Kaul","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0065","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","article-title":"A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2021.03.007_bib0066","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.26028","article-title":"Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria","volume":"96","author":"Onalo","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0067","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/JPR.S131156","article-title":"Subanesthetic ketamine for pain management in hospitalized children, adolescents, and young adults: a single-center cohort study","volume":"10","author":"Sheehy","year":"2017","journal-title":"J Pain Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0068","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1515\/sjpain-2017-0140","article-title":"Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial","volume":"18","author":"Lubega","year":"2018","journal-title":"Scand J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0069","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/AJP.0000000000000289","article-title":"Psychosocial and functional outcomes in youth with chronic sickle cell pain","volume":"32","author":"Sil","year":"2016","journal-title":"Clin J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0070","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/blood.V92.7.2551","article-title":"Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis","volume":"92","author":"Graido-Gonzalez","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0071","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2141.1994.tb08318.x","article-title":"Circulating cytokines in sickle cell patients during steady state","volume":"87","author":"Croizat","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0072","first-page":"611","article-title":"Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease","volume":"84","author":"Francis","year":"1992","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.trsl.2021.03.007_bib0073","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1189\/jlb.0708445","article-title":"Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy","volume":"85","author":"Lanaro","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0074","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neulet.2019.02.008","article-title":"Immune cell neural interactions and their contributions to sickle cell disease","volume":"699","author":"Sagi","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.trsl.2021.03.007_bib0075","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.3324\/haematol.2015.137489","article-title":"Spinal glial activation and oxidative stress are alleviated by treatment with curcumin or coenzyme Q in sickle mice","volume":"101","author":"Valverde","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2021.03.007_bib0076","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2015.136523","article-title":"Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation","volume":"101","author":"Vincent","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2021.03.007_bib0077","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/imr.12622","article-title":"Mast cell-neural interactions contribute to pain and itch","volume":"282","author":"Gupta","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.trsl.2021.03.007_bib0078","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/j.pain.0000000000000104","article-title":"Sensitization of nociceptive spinal neurons contributes to pain in a transgenic model of sickle cell disease","volume":"156","author":"Cataldo","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0079","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/j.pain.0000000000000966","article-title":"Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis","volume":"158","author":"Uhelski","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.23341","article-title":"Patients with sickle cell disease have increased sensitivity to cold and heat","volume":"88","author":"Brandow","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0081","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2141.2011.08977.x","article-title":"Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness","volume":"156","author":"Cain","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0082","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jpain.2016.01.475","article-title":"An evaluation of central sensitization in patients with sickle cell disease","volume":"17","author":"Campbell","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0083","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2010-12-327429","article-title":"Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease","volume":"11","author":"Hillery","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0084","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2010-01-260372","article-title":"Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids","volume":"116","author":"Kohli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160608","article-title":"Comparative analysis of pain behaviours in humanized mouse models of sickle cell anemia","volume":"11","author":"Lei","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.03.007_bib0086","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MPH.0000000000000214","article-title":"Sensory and thermal quantitative testing in children with sickle cell disease","volume":"37","author":"Jacob","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0087","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jpain.2015.07.005","article-title":"Frequency of hospitalizations for pain and association with altered brain network connectivity in sickle cell disease","volume":"16","author":"Darbari","year":"2015","journal-title":"J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0088","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejpain.2004.11.001","article-title":"Human brain mechanisms of pain perception and regulation in health and disease","volume":"9","author":"Apkarian","year":"2005","journal-title":"Eur J Pain"},{"issue":"Suppl 1","key":"10.1016\/j.trsl.2021.03.007_bib0089","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/j.pain.0000000000000798","article-title":"Reward, motivation, and emotion of pain and its relief","volume":"158","author":"Porreca","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.mcna.2017.04.012","article-title":"Integrative Pain Management","volume":"101","author":"Bonakdar","year":"2017","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.trsl.2021.03.007_bib0091","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpain.2017.08.010","article-title":"Daily opioid use fluctuates as a function of pain, catastrophizing, and affect in patients with sickle cell disease: an electronic daily diary analysis","volume":"19","author":"Finan","year":"2018","journal-title":"J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0092","unstructured":"Williams Z, Hardy S, Berger C, et\u00a0al. Cognitive and emotional factors and pain-related outcomes in youth with sickle cell disease. In: ASH; 2020. Accessed December 27, 2020. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper141969.html"},{"key":"10.1016\/j.trsl.2021.03.007_bib0093","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2020.06.025","article-title":"The gut microbiome regulates psychological-stress-induced inflammation","volume":"53","author":"Xu","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2021.03.007_bib0094","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41591-019-0409-3","article-title":"Seasonal manifestations of sickle cell disease activity","volume":"25","author":"Xu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fncel.2019.00056","article-title":"Mast cells induce blood brain barrier damage in SCD by causing endoplasmic reticulum stress in the endothelium","volume":"13","author":"Tran","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.trsl.2021.03.007_bib0096","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/ejh.13461","article-title":"Characteristics and potential biomarkers of adult sickle cell patients with chronic pain","volume":"105","author":"Albo","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0097","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/bjh.14300","article-title":"Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use","volume":"175","author":"Brandow","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0098","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V92.9.3148","article-title":"Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis","volume":"92","author":"Michaels","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0099","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.2147\/JPR.S210196","article-title":"Substance P modulates electroacupuncture analgesia in humanized mice with sickle cell disease","volume":"12","author":"Wang","year":"2019","journal-title":"J Pain Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9123902","article-title":"Considerations for cannabis use to treat pain in sickle cell disease","volume":"9","author":"Argueta","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0101","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.10874","article-title":"Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial","volume":"3","author":"Abrams","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.trsl.2021.03.007_bib0102","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMp058165","article-title":"Medical marijuana and the Supreme Court","volume":"353","author":"Okie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0103","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMp1000695","article-title":"Medical marijuana and the law","volume":"362","author":"Hoffmann","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0104","unstructured":"State Medical Marijuana Laws. NCSL. Accessed December 25, 2020. https:\/\/www.ncsl.org\/research\/health\/state-medical-marijuana-laws.aspx"},{"key":"10.1016\/j.trsl.2021.03.007_bib0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/07418825.2012.761721","article-title":"Examining racial disparities in drug arrests","volume":"32","author":"Mitchell","year":"2015","journal-title":"Justice Quarterly"},{"key":"10.1016\/j.trsl.2021.03.007_bib0106","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1182\/bloodadvances.2020002325","article-title":"Medical marijuana certification for patients with sickle cell disease: a report of a single center experience","volume":"4","author":"Curtis","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.trsl.2021.03.007_bib0107","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/can.2019.0036","article-title":"Daily cannabis users with sickle cell disease show fewer admissions than others with similar pain complaints","volume":"5","author":"Curtis","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"issue":"suppl 1","key":"10.1016\/j.trsl.2021.03.007_bib0108","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2018-99-118290","article-title":"Medical marijuana for sickle cell disease: results of two years of certification in an adult sickle cell center","volume":"132","author":"Curtis","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trsl.2021.03.007_bib0109","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13643-017-0541-4","article-title":"Structural barriers in access to medical marijuana in the USA-a systematic review protocol","volume":"6","author":"Valencia","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.trsl.2021.03.007_bib0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/DBP.0000000000000381","article-title":"Perceived racial bias and health-related stigma among youth with sickle cell disease","volume":"38","author":"Wakefield","year":"2017","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.trsl.2021.03.007_bib0111","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/1359105314539530","article-title":"The measure of sickle cell stigma: initial findings from the improving patient outcomes through respect and trust study","volume":"21","author":"Bediako","year":"2016","journal-title":"J Health Psychol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0112","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2018-11-876839","article-title":"Bad weed: synthetic cannabinoid-associated coagulopathy","volume":"133","author":"Arepally","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0113","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1001\/jama.2019.17361","article-title":"Cannabidiol products are everywhere, but should people be using them?","volume":"322","author":"Rubin","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.03.007_bib0114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"MacCallum","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0115","doi-asserted-by":"crossref","first-page":"g6997","DOI":"10.1136\/bmj.g6997","article-title":"Medical cannabis: US researchers battle for access to the plant","volume":"349","author":"Frisch","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.trsl.2021.03.007_bib0116","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/S0043-31442006000400004","article-title":"The prevalence of marijuana smoking in young adults with sickle cell disease: a longitudinal study","volume":"55","author":"Knight-Madden","year":"2006","journal-title":"West Indian Med J"},{"key":"10.1016\/j.trsl.2021.03.007_bib0117","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm.3852","article-title":"The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase","volume":"21","author":"Vicu\u00f1a","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.03.007_bib0118","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood.V128.22.858.858","article-title":"Regulation of elastase by serpinA3N contributes to pain in sickle cell disease","volume":"128","author":"Aich","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2021.03.007_bib0119","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2017.51","article-title":"Transcriptomic analysis of gene signatures associated with sickle pain","volume":"4","author":"Paul","year":"2017","journal-title":"Sci Data"},{"key":"10.1016\/j.trsl.2021.03.007_bib0120","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3324\/haematol.2013.088021","article-title":"Nucleosomes and neutrophil activation in sickle cell disease painful crisis","volume":"98","author":"Schimmel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2021.03.007_bib0121","doi-asserted-by":"crossref","first-page":"H1679","DOI":"10.1152\/ajpheart.00256.2006","article-title":"Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells","volume":"291","author":"Haynes","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0122","first-page":"621","article-title":"Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome","volume":"10","author":"Aikawa","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.trsl.2021.03.007_bib0123","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1442-2050.2007.00699.x","article-title":"Neutrophil elastase inhibitor improves postoperative clinical courses after thoracic esophagectomy","volume":"20","author":"Suda","year":"2007","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.trsl.2021.03.007_bib0124","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0006-8993(02)02932-3","article-title":"Localization of CaMKIIalpha in rat primary sensory neurons: increase in inflammation","volume":"947","author":"Carlton","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0169-328X(00)00265-5","article-title":"Colocalization of the mu-opioid receptor and calcium\/calmodulin-dependent kinase II in distinct pain-processing brain regions","volume":"85","author":"Br\u00fcggemann","year":"2000","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0126","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1523\/JNEUROSCI.4346-09.2010","article-title":"Ca2+\/Calmodulin-dependent protein kinase II is required for the initiation and maintenance of opioid-induced hyperalgesia","volume":"30","author":"Chen","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.trsl.2021.03.007_bib0127","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1097\/j.pain.0000000000000704","article-title":"CaMKII\u03b1 underlies spontaneous and evoked pain behaviors in Berkeley sickle cell transgenic mice","volume":"157","author":"He","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejphar.2013.10.062","article-title":"Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease","volume":"723","author":"Molokie","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)80235-1","article-title":"ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization","volume":"341","author":"Mollereau","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.trsl.2021.03.007_bib0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0891-0618(01)00135-1","article-title":"Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain","volume":"22","author":"Neal","year":"2001","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.trsl.2021.03.007_bib0131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-2999(98)00216-7","article-title":"Inhibition of nociceptin on sensory neuropeptide release and mast cell-mediated plasma extravasation in rats","volume":"347","author":"N\u00e9meth","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0132","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3324\/haematol.2015.128736","article-title":"Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice","volume":"100","author":"Vang","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2021.03.007_bib0133","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1124\/jpet.111.184663","article-title":"Differential effects of nociceptin\/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP\/\u03bc receptor agonists in the sciatic nerve ligation chronic pain model in mice","volume":"339","author":"Khroyan","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trsl.2021.03.007_bib0134","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1016\/j.bmc.2010.07.034","volume":"18","author":"Hayashi","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.trsl.2021.03.007_bib0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pain.2005.03.012","article-title":"Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat","volume":"116","author":"Obara","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0136","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MPH.0000000000000265","article-title":"The use of neuropathic pain drugs in children with sickle cell disease is associated with older age, female sex, and longer length of hospital stay","volume":"37","author":"Brandow","year":"2015","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0137","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/s41598-021-81654-1","article-title":"Diet and companionship modulate pain via a serotonergic mechanism","volume":"11","author":"Tran","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2021.03.007_bib0138","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pbc.24838","article-title":"Neuropathic pain in patients with sickle cell disease","volume":"61","author":"Brandow","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.trsl.2021.03.007_bib0139","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pain.2012.10.001","article-title":"Predictors of severe pain in a cohort of 5271 individuals with self-reported neuropathic pain","volume":"154","author":"Butler","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0141","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/pbc.22874","article-title":"The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations","volume":"56","author":"Brandow","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.trsl.2021.03.007_bib0142","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.16067","article-title":"Gabapentin alleviates chronic spontaneous pain and acute hypoxia-related pain in a mouse model of sickle cell disease","volume":"187","author":"Sadler","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0143","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.21873","article-title":"Pain management in children and adolescents with sickle cell disease","volume":"86","author":"Jerrell","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134192","article-title":"The effectiveness of cognitive behavioural treatment for non-specific low back pain: a systematic review and meta-analysis","volume":"10","author":"Richmond","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.03.007_bib0145","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/AJP.0000000000000183","article-title":"Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones","volume":"31","author":"Schatz","year":"2015","journal-title":"Clin J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0146","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MPH.0b013e3181e793f9","article-title":"A family-based randomized controlled trial of pain intervention for adolescents with sickle cell disease","volume":"32","author":"Barakat","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0147","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13557850123965","article-title":"Cognitive-behavioural therapy for the management of sickle cell disease pain: identification and assessment of costs","volume":"6","author":"Thomas","year":"2001","journal-title":"Ethn Health"},{"key":"10.1016\/j.trsl.2021.03.007_bib0148","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.NAJ.0000445680.06812.6a","article-title":"Original research: using guided imagery to manage pain in young children with sickle cell disease","volume":"114","author":"Dobson","year":"2014","journal-title":"Am J Nurs"},{"key":"10.1016\/j.trsl.2021.03.007_bib0149","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/jan.12895","article-title":"A randomized controlled pilot study feasibility of a tablet-based guided audio-visual relaxation intervention for reducing stress and pain in adults with sickle cell disease","volume":"72","author":"Ezenwa","year":"2016","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.trsl.2021.03.007_bib0150","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2147\/JPR.S131859","article-title":"The effect of hypnosis on pain and peripheral blood flow in sickle-cell disease: a pilot study","volume":"10","author":"Bhatt","year":"2017","journal-title":"J Pain Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0151","doi-asserted-by":"crossref","first-page":"e27525","DOI":"10.1002\/pbc.27525","article-title":"Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease","volume":"66","author":"Agrawal","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.trsl.2021.03.007_bib0152","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-244X-14-207","article-title":"Sleep disturbance, depression and pain in adults with sickle cell disease","volume":"14","author":"Wallen","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.trsl.2021.03.007_bib0153","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jpain.2015.03.010","article-title":"The effect of sleep continuity on pain in adults with sickle cell disease","volume":"16","author":"Moscou-Jackson","year":"2015","journal-title":"J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0154","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ajh.26014","article-title":"Nocturnal peripheral vasoconstriction predicts the frequency of severe acute pain episodes in children with sickle cell disease","volume":"96","author":"Chalacheva","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0155","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jpainsymman.2016.12.351","article-title":"A randomized trial of yoga for children hospitalized with sickle cell vaso-occlusive crisis","volume":"53","author":"Moody","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.trsl.2021.03.007_bib0156","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/AJP.0000000000000036","article-title":"A retrospective review of acupuncture use for the treatment of pain in sickle cell disease patients: descriptive analysis from a single institution","volume":"30","author":"Lu","year":"2014","journal-title":"Clin J Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0157","doi-asserted-by":"crossref","first-page":"34493","DOI":"10.1038\/srep34493","article-title":"Electroacupuncture in conscious free-moving mice reduces pain by ameliorating peripheral and central nociceptive mechanisms","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2021.03.007_bib0158","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jpepsy\/jsp015","article-title":"A randomized controlled trial of massage therapy in children with sickle cell disease","volume":"34","author":"Lemanek","year":"2009","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0159","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0031-6997(25)06841-3","article-title":"Precursor control of neurotransmitter synthesis","volume":"32","author":"Wurtman","year":"1980","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.trsl.2021.03.007_bib0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00213-008-1254-0","article-title":"Effect of different tryptophan sources on amino acids availability to the brain and mood in healthy volunteers","volume":"201","author":"Markus","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"6 Suppl 1","key":"10.1016\/j.trsl.2021.03.007_bib0161","article-title":"Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain","volume":"137","author":"Fernstrom","year":"2007","journal-title":"J Nutr"},{"key":"10.1016\/j.trsl.2021.03.007_bib0162","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.3324\/haematol.2018.208322","article-title":"Diet and gender influence survival of transgenic Berkley sickle cell mice","volume":"104","author":"Jahagirdar","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.trsl.2021.03.007_bib0163","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2018021444","article-title":"Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)","volume":"2","author":"Daak","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.trsl.2021.03.007_bib0164","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12291-012-0277-9","article-title":"Hematological parameters and RBC TBARS Level of Q 10 supplemented tribal sickle cell patients: a hospital based study","volume":"28","author":"Thakur","year":"2013","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.trsl.2021.03.007_bib0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00776-014-0633-0","article-title":"Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study","volume":"19","author":"Nakagawa","year":"2014","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.trsl.2021.03.007_bib0166","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","article-title":"Therapeutic roles of curcumin: lessons learned from clinical trials","volume":"15","author":"Gupta","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.trsl.2021.03.007_bib0167","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/j.pain.0000000000001407","article-title":"Children and adolescents with sickle cell disease have worse cold and mechanical hypersensitivity during acute painful events","volume":"160","author":"Brandow","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nicl.2016.12.024","article-title":"Characterization of functional brain activity and connectivity using EEG and fMRI in patients with sickle cell disease","volume":"14","author":"Case","year":"2017","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.trsl.2021.03.007_bib0169","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/bloodadvances.2019000882","article-title":"End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.trsl.2021.03.007_bib0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.23341","article-title":"Patients with sickle cell disease have increased sensitivity to cold and heat","volume":"88","author":"Brandow","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0171","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/j.pain.0000000000000473","article-title":"Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls","volume":"157","author":"Campbell","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0172","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/papr.12841","article-title":"A QST-based pain phenotype in adults with sickle cell disease: sensitivity and specificity of quality descriptors","volume":"20","author":"Dyal","year":"2020","journal-title":"Pain Pract"},{"key":"10.1016\/j.trsl.2021.03.007_bib0173","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MPH.0000000000000532","article-title":"Clinical interpretation of quantitative sensory testing as a measure of pain sensitivity in patients with sickle cell disease","volume":"38","author":"Brandow","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0174","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JPR.S150066","article-title":"Quantitativesensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode","volume":"11","author":"Bakshi","year":"2018","journal-title":"J Pain Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0175","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nmeth.1455","article-title":"Coding of facial expressions of pain in the laboratory mouse","volume":"7","author":"Langford","year":"2010","journal-title":"Nat Methods"},{"key":"10.1016\/j.trsl.2021.03.007_bib0176","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bcmd.2015.12.006","article-title":"Quantification of pain in sickle mice using facial expressions and body measurements","volume":"57","author":"Mittal","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.trsl.2021.03.007_bib0177","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1109\/TSMCB.2010.2082525","article-title":"Automatically detecting pain in video through facial action units","volume":"41","author":"Lucey","year":"2011","journal-title":"IEEE Trans Syst Man Cybern B Cybern"},{"key":"10.1016\/j.trsl.2021.03.007_bib0178","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0304-3959(87)90073-X","article-title":"Pain expression in neonates: facial action and cry","volume":"28","author":"Grunau","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0179","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pain.2008.04.010","article-title":"The structure, reliability and validity of pain expression: evidence from patients with shoulder pain","volume":"139","author":"Prkachin","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.trsl.2021.03.007_bib0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.561947","article-title":"Spatiotemporal alterations in gait in humanized transgenic sickle mice","volume":"11","author":"Kiven","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2021.03.007_bib0181","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2018.11.009","article-title":"Graph theory analysis reveals how sickle cell disease impacts neural networks of patients with more severe disease","volume":"21","author":"Case","year":"2019","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.trsl.2021.03.007_bib0182","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JPR.S145581","article-title":"Increased theta band EEG power in sickle cell disease patients","volume":"11","author":"Case","year":"2018","journal-title":"J Pain Res"},{"key":"10.1016\/j.trsl.2021.03.007_bib0183","unstructured":"PainQx. PainQx. Accessed December 27, 2020. https:\/\/painqx.com\/our-story\/"},{"key":"10.1016\/j.trsl.2021.03.007_bib0184","article-title":"Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by electronic patient-reported outcomes, actigraphy, and biomarkers","author":"Pittman","year":"2020","journal-title":"Blood"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:45:19Z","timestamp":1761828319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524421000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":184,"alternative-id":["S1931524421000578"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2021.03.007","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pain in sickle cell disease: current and potential translational therapies","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2021.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}